This document discusses the imaging features of common benign and malignant hepatic lesions. It begins by outlining the objectives and introducing the increasing detection of hepatic masses on imaging. It then covers the classification and workup of hepatic lesions. The main body discusses the imaging appearance and diagnostic criteria of common benign lesions like hemangiomas, FNH, and cysts. It also covers malignant lesions such as HCC, metastases, and their characteristic enhancement patterns and imaging findings on ultrasound, CT, and MRI that are used for diagnosis.
2. Objective :
1. Identify the most important imaging
features of common benign liver tumors
2. Identify the most important imaging
features of malignant lesions
3. Know the diagnosis of hepatocellular
carcinoma
3. Introduction
• Extensive use of imaging studies has
increased the detection rates of hepatic
lesions
• A mass can be found either incidentally or
during screening for liver cancer in patients
with cirrhosis
• These can be benignant or malignant and
thus the right approach for assessing these
masses is important
7. Hepatic Hemangiomas
• Benign vascular lesions of liver.
• The commonest liver tumor
• More common in female
• May range in size from 1cm to >10 cm
• 3-5 decades
• Usually asymptomatic
• Incidental discovry: US
9. Hepatic Hemangiomas
US: well-defined, uniformly hyperechoic liver mass with peripheral feeder
vessels that are characteristic of a hemangioma.
Posterior acoustic enhancment.
Cavernous
angiomas
10. Hepatic Hemangiomas
CT: The pathognomonic features of caverneous hemangioma: peripheral
nodular and discontinuous enhancement and progressive centripetal fill-in
The attenuation of the enhancement is similar to the aorta.
IV-
HAP
PVP
DP
12. Hepatic Hemangiomas
Diagnosis
MRI:
. Hypointense and well defined in T1
. Marked hyperintensity that increases with echo time on
T2
. The same caracteristic pattern of enhacement as is seen
at CT
15. Focal Nodular Hyperplasia (FNH)
. Benign nodule formation of normal liver tissue with no malignant
potential.
. 2nd most common benign hepatic lesion
. More common in young and middle age women
. Male to female :5-17
. Usually asymptomatic
. May cause minimal pain
. Response of parenchyma to a vascular malformation or portal duct injury.
16. Focal Nodular Hyperplasia (FNH)
. Hyperplasia with a central
stellate scar radiating in
to distinct nodules.
.the scar is due to Ductular
diffentiation and
malformed vessels.
. Rarely- encapsulated and
pedunculated.
.
17. Focal Nodular Hyperplasia (FNH)
Diagnosis:
US: usually non- specific, Nodule with varying
echogenicity commonly isoechoicto to normal
liver.
The scar is not usually seen on US.
Color Doppler imaging may show central vessels
with spoke wheel configuration
18. Focal Nodular Hyperplasia (FNH)
Diagnosis: CT
. Central scar formed by a ductules and venules rather than a true
fibrous scar.
. Brisk homogeneous enhancement with quick wash out. In the
portovenous phase it will only shows unenhanced scar. Usually th e
scar shows late enhancment
. Well defined
. Early homogenesation
. Hypodense fibrous bands and septa that arise from the scar
. On delayed phase images the central scar may remain
hyperattenuating
. Without capsule
21. Focal Nodular Hyperplasia (FNH)
Diagnosis:MRI typical finding
. Isointense to hypointense on T1-weighted images
. Slightly hyperintense to isointense on T2-weighted images
. Brisk homogeneous enhancement
. Delayed enhancement of the central scar
23. Hepatic Adenoma
. Rare hepatic tumor
. Women aged 20 to 40 years
. Association with oral contraceptive use
. Solitary (70%–80%)
. Can be associated with right upper-quadrant pain
. Risk of rupture, hemorrhage, or malignant transformation
. they are usually resected
. Benign neoplasm composed of normal hepatocytes
scattered kupffer cells and no bile ducts. “negative in hIDA
scan”.
Surrounded by a psuedocapsule tends to enhance late
24. Hepatic Adenoma
US:
. Nonspecific, adenomas may be hypo, iso, or hyperechoic but are typically
heterogeneous
CT:
. Non specific apperance , usually Well circumscribed hypoense mass which
shows hetrogenous enhancment hetrougenous lesion without lobulation
. Heterogeneous because of their mixed components of fat, hemorrhage, and
necrosis
. Diffuse heterogeneous arterial enhancement and iso attenuated on delayed scan
MRI:
. Hyper to isointense on T1 (hemorrhage) and slightly hyperintense on T2 weighted
images
. Same appearance on contrast-enhanced image as CT scan
26. Liver cysts:
. May be single or multiple
. May be part of polycystic kidney disease or Biliary hamartomas
. Patients often asymptomatic
. No specific management required
27. Liver cysts:
. US is sufficient to diagnose
. On CT scan or MRI hepatic cysts are typically discovered incidentally
Well defined and low in densitywith internal attenuation of water.
No enhancment on any phase of the post contrast scans.
30. Hepatocellular Carcinoma (HCC)
•The most common primary tumour liver tumor.
•Rarely occurs before age of 40 and peaks at 70 years
•Male to female: 4/1
•Cirrhosis is the strongest predisposing factor for HCC
•HCC is locally invasive and tends to invade the portal vien, IVC and bile
ducts.
•Most HCCs develop by means of a multistep progression: from a low-
grade dysplastic nodule to a high-grade dysplastic nodule, to a
dysplastic nodule with a focus of HCC, and finally to convert carcinoma.
31. Usually too small to detect by imaging
–May be surrounded by fibrotic septa
–May contain iron, copper
Siderotic regenerating nodules
–Hyperdense on NCCT, disappear on HAP & PVP
–Variable on T1, Hypointense on T2 MR, “bloom” on GRE
-completely supplied by portal vein and it’s not premalignant.
Regenerating Nodules
32. Dysplastic Nodules
A premalignant lesion.
No arterial enhancement
Iso to hyperintense on T1 (copper)
Iso to Hypo on T2 (opposite of HCC)
Should not enhance much on hypervascular liver lesions
33. Hepatocellular Carcinoma (HCC)
AFP (Alfa feto protein)
Is an HCC tumor marker
Values more than 100ng/ml are highly suggestive of HCC
Elevation seen in more than 70%
34. Hepatocellular Carcinoma (HCC)
US : hyperechoic, smaller tumors are hypoechoic.
Heterogeneous, hypervascular
US sensitivity about 75%.
35. Arterial Phase:
liver(30-35 sec)
HCC as supplied by arterial branch/neovascularization
Hepatocellular Carcinoma (HCC)
Venous Phase:
HCC which is enhanced during arterial phase has lost its contrast,
hence no enhancement of the tumor but rest of the liver enhances.
Contrast in brightness of the lesion with respect to surrounding liver.
Enhancement
Wash out phenomenan
CT or MR
36. Hepatocellular Carcinoma (HCC)
Delayed Phase :
Wash -out phenomenan persists and often exaggerated in smaller
lesions.
The tumor capsule
IV-
HAP
PVP
DP
capsule
38. MRI
. Variable intensity of HCC on T1
. 35% hyper, 25% iso-, 40 % hypo
. Hyperintense (T1) often well-differentiated, contain fat, copper,
glycogene
. Almost always hyperintense on T2 MR
. The tumor capsule is hypointense on both T1- and T2-weighted
images in most cases
. Other Features: Focal fat
Hepatocellular Carcinoma (HCC)
41. Fibro-Lamellar Carcinoma
. Presents in young pt (5-35)
. Not related to cirrhosis, AFP is normal
. CT/MRI shows large mass with peripheral enhancement and typical stellate scar with
radial septa showing persistant enhancement
. Calcifications
42. Metastatic disease
. Most common malignant hepatic tumor
. Presence of extrahepatic malignancy should be sought in patients with
characteristic liver lesions per imaging studies. Physical exam and
history is very helpful.
. Common primaries : colon, breast, lung, stomach, pancreases, and
melanoma
. Mild cholestatic picture (ALP, LDH) with preserved liver function
. CT or US guided biopsy provides definitive diagnosis but not always
required.
43. Metastatic disease
Variable US features+++
Iso, hyper or hypo echoic++
Contrast-enhanced US (CEUS) (84% accuracy)
Intraoperative US (IOUS) (96% accuracy)
Typical feature
44. Metastatic disease
. Most liver metastases are hypovascular and are best imaged during the
portal venous phase (colon, stomach and pancreas)
. Hypervascular metastases enhancing on the arterial phase (neuroendocrine
tumors, renal cell, breast, melanoma, thyroid)
. Calcification may be present with metastases from mucinous
gastrointestinal tract tumors and from primary ovarian, breast, lung, renal,
and thyroid cancer
. Other features : Hemorrhagic or cystic metastases
45. Metastatic disease
. On MRI, metastases are variable but are usually hypo- to isointense on T WI and
iso- to hyperintense on T2 WI
. Metastatic tumors with liquefactive necrosis or cystic neoplasms show higher signal
intensity on T2 WI
. Metastases may show central hypointensity on T2WI (coagulative necrosis, fibrin,
and mucin)
. High T1 signal intensity can be seen with metastases from melanoma, colonic
adenocarcinoma, ovarian adenocarcinoma, multiple myeloma and pancreatic
mucinous cystic tumor
. Comparing T2-weighted (TE 90) and T2-weighted (TE 160) sequences, metastases
become less intense Characterization
. T1-weighted 3D dynamic contrast-enhanced MRI Detection
46. Wide spectrum of apperance on CT
depends on the primary neoplasm
•Well defined , low density soli mass with
peripheral enhancement e.g. Colon cancer
•Hypervascular metastasis show diffused
enhancement on arterial phase.
•Can be calcified when the primary neoplasm is
mucinous adenocarcinomas, osteocarcinoma,
chondrosarcoma.
•Cystic metastasis from mucinous colon
carcinoma, carcinoid or lung.
48. Conclusion :
. MDCT and MRI are the most commonly used imaging
modalities for detection and characterization of focal hepatic
lesion
. Imaging modalities can make diagnosis for:
Hepatic cyst
Caverneous hemangioma
Typical FNH
HCC
. For others lesions biopsy will be often necessary
Editor's Notes
Things to consider usually
The patient is usually has otherwise normal appering liver , normal LFT, no known hx of malignancy, asymptomatic.
The apperance of the hemangoma in nonenhanced CT is usually hypodense liver lesion.
Gaint hemangiomas tend to have a nonenhancing central area representing cystic degeneration.
In contrast to metastatic liver which tend to invase locally.